Form D · Biotechnology
Orna Therapeutics Holdings, LLC
Cambridge, MA · CIK 0001943348
Offering snapshot reported Aug 23, 2022 · SEC filing
- Reported sold
- $121M Offering amount: $300M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 23, 2022 | Initial | $120,599,993 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456682
Source: Form D, filed Aug 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Anderson | Director |
| Sakae Asanuma | Director |
| Thomas M. Barnes | Director, Executive |
| Thomas Ebeling | Director |
| Ansbert Gadicke | Director |
| Brian Goodman | Director |
| Morana Jovan Embiricos | Director |
| Nishla Keiser | Executive |
| Robert Marby | Executive |
| Francesco Marincola | Director |
| John Mc Cabe | Executive |
| William Shen | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
620 Memorial Drive 2 Nd Floor
Cambridge, MA, 02139
Cambridge, MA, 02139